Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.38 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.34 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7559400 | 0.88 | TSHR (0.38) | TSHRBTN3A1 | |
| SCHEMBL14992893 | 0.83 | TSHR (0.57) | LPAR3LPAR2LPAR1TSHRP2RY10 | |
| SCHEMBL27813919 | 0.83 | TSHR (0.57) | LPAR3LPAR2LPAR1TSHRP2RY10 | |
| SCHEMBL27785449 | 0.83 | TSHR (0.57) | LPAR3LPAR2LPAR1TSHRP2RY10 | |
| SCHEMBL27834064 | 0.83 | TSHR (0.57) | LPAR3LPAR2LPAR1TSHRP2RY10 | |
| SCHEMBL25430754 | 0.83 | TSHR (0.57) | LPAR3LPAR2LPAR1TSHRP2RY10 | |
| SCHEMBL28325465 | 0.81 | TSHR (0.54) | LPAR3LPAR2LPAR1TSHRP2RY10 | |
| SCHEMBL29176806 | 0.81 | TSHR (0.39) | LPAR3LPAR2LPAR1TSHRBTN3A1 | |
| SCHEMBL28080528 | 0.80 | BTN3A1 (0.39) | LPAR3LPAR2LPAR1TSHRBTN3A1 | |
| SCHEMBL27881679 | 0.80 | TSHR (0.47) | LPAR3LPAR2LPAR1TSHRBTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040208834-A1 | Oral-use polymer and oral-use composition | KAO CORPORATION (JP) | 2004-10-21 | — | — | US | disclosed |
| EP-1413589-A1 | POLYMERS FOR ORAL USE AND COMPOSITIONS FOR ORAL USE | Kao Corporation (JP) | 2004-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040208834-A1 | Oral-use polymer and oral-use composition | PHOSPHO1, PPA1, PHPT1 | LPAR3 1113/4885LPAR2 858/4885LPAR1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.